Hims has also secured a California peptide facility while the FDA decides whether to allow compounding of BPC-157 and five other peptides an advisory panel backed.
Recap by typeshit. Full story at Stocktwits.
General exercise advice aimed at GLP-1 users, shared on Facebook with no study or expert named in the material available.
Gilead takes global rights to the Shanghai biotech's program, led by HCXT-2001, an oral peptide that could compete with injected IBD drugs.
A Facebook promo for a podcast episode on the ripple effects of GLP-1 consumers across businesses. Few details beyond the pitch.
10:49
xitsnemox posts a short check-in from week 14 on oral Wegovy, two weeks after stepping up to the 25mg tablet. A personal account, not medical advice.
A short BusinessWorld Online piece on what the newest weight loss pill is called. Little detail is available beyond the title.
Ingredient makers tell Nutrition Insight that companion products need trial evidence and careful claims, with HTBA pointing to fatigue on treatment.
Loading…